Browsing Tag
cancer research
23 posts
AACR Annual Meeting 2026: what cancer researchers and pharma professionals need to know before San Diego
AACR Annual Meeting 2026 runs April 17-22 at San Diego Convention Center. Over 7,400 abstracts, six plenaries, AI, CAR T, ADCs and RAS inhibitor data.
The future of biomedical research? Illumina’s spatial transcriptomics could unlock unprecedented discoveries
Illumina, Inc. has introduced an innovative spatial transcriptomics technology, designed to significantly enhance the mapping of complex tissues…
The rising impact of Melanoma: Understanding the risks, causes, and advances in treatment
Melanoma, a severe form of skin cancer, originates in melanocytes, the pigment-producing cells responsible for skin color. Known…
Aptevo Therapeutics achieves major breakthrough with mipletamig in acute myeloid leukemia
Aptevo Therapeutics has unveiled remarkable findings from Cohort 1 of its RAINIER clinical trial for mipletamig, a bispecific…
Oxford Nanopore and UK Biobank to pioneer future of personalised medicine
In a major breakthrough for biomedical research, Oxford Nanopore Technologies and UK Biobank have announced a landmark collaboration…
OncoVerity accelerates AML treatment with Series A extension
OncoVerity, a leader in integrating bioinformatics with oncology drug development, has closed a Series A extension financing round,…
Amplia Therapeutics secures FDA fast track status for narmafotinib in pancreatic cancer, stock surges
Amplia Therapeutics Limited (ASX: ATX) has announced that its Focal Adhesion Kinase (FAK) inhibitor, narmafotinib, has been granted…
Breakthrough in breast cancer treatment? BriaCell Therapeutics shares soar 150%!
BriaCell Therapeutics Corp., a clinical-stage biotechnology company, saw its shares surge by more than 150% to $1.55 following…
Roche reports setback in lung cancer study with tiragolumab and tecentriq combination
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced disappointing results from the phase II/III SKYSCRAPER-06 study, aimed at…
Hinova Pharmaceuticals’ HP518 gets FDA fast track designation in triple-negative breast cancer
Hinova Pharmaceuticals Inc. (688302.SH), a trailblazer in the biopharmaceutical industry, has achieved a significant milestone with the U.S.…